All In Biotech

NDA 208723 · Actavis LLC

Levoleucovorin Calcium

Levoleucovorin Calcium · Intravenous

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Sep 29, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,253

339 Phase 3, 166 recruiting

FAERS reports

3,810

3,758 serious, 549 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 29, 2016 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
  • LEVOLEUCOVORIN CALCIUM · LEVOLEUCOVORIN CALCIUM EQ 175MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Levoleucovorin" as an intervention, any sponsor and status, largest first.

All 1,253 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea303
  • off label use280
  • neutropenia259
  • diarrhoea254
  • decreased appetite191
  • vomiting179
  • malignant neoplasm progression169
  • neuropathy peripheral159
  • pyrexia144
  • asthenia141
  • neutrophil count decreased141
  • myelosuppression136

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20071
20086
200916
20102
2011112
2012195
20139
201419
201521
201610
201715
2018113
201989
202077
2021266
2022482
2023804
2024593
2025614
2026365

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Levoleucovorin Calcium (Levoleucovorin Calcium)

2024 spending

$9K

Beneficiaries

n/a

29 claims

Per beneficiary

n/a

$3.64 per unit

View as table
YearSpending
2020$77,847
2021$69,840
2022$12,035
2023$13,137
2024$8,605

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Actavis LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.